Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lübbert

Showing results (21-30 of 248) with videos related to

Pageof 25
Sort By:
Seminars in Cancer Biology|November 14, 2017
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemiaChristian Flotho, Sebastian Sommer, Michael Lübbert
Clinical Epigenetics|May 26, 2016
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyLudovica Morera, Michael Lübbert, Manfred Jung
Journal of Cancer Research and Clinical Oncology|May 27, 2015
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acidGabriele Greve, Insa Schiffmann, Michael Lübbert
Journal of Cellular Biochemistry|April 12, 2003
Upstream and downstream targets of RUNX proteinsFlorian Otto, Michael Lübbert, Michael Stock
Expert Opinion on Therapeutic Targets|March 11, 2005
The silence of the genes: epigenetic disturbances in haematopoietic malignanciesBjörn Hackanson, Yalin Guo, Michael Lübbert
Current Opinion in Hematology|January 19, 2017
Innovative strategies for adverse karyotype acute myeloid leukemiaSabine Blum, Gabriele Greve, Michael Lübbert
Current Opinion in Hematology|January 12, 2010
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?Utz Krug, Michael Lübbert, Thomas Büchner
International Journal of Hematology|October 16, 2004
DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemiaBjörn Rüter, Pierre W Wijermans, Michael Lübbert
Blood|April 23, 2003
Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresesKarl-Georg Fischer, Barbara Deschler, Michael Lübbert
Haematologica|May 29, 2025
"Dexamethasing" acute myeloid leukemia: new opportunities for an "old" drugJesús Duque-Afonso, Julian List, Michael Lübbert
Pageof 25

Showing results (21-30 of 248) with videos related to

Sort By:
Pageof 25
Seminars in Cancer Biology|November 14, 2017
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemiaChristian Flotho, Sebastian Sommer, Michael Lübbert
Clinical Epigenetics|May 26, 2016
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyLudovica Morera, Michael Lübbert, Manfred Jung
Journal of Cancer Research and Clinical Oncology|May 27, 2015
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acidGabriele Greve, Insa Schiffmann, Michael Lübbert
Journal of Cellular Biochemistry|April 12, 2003
Upstream and downstream targets of RUNX proteinsFlorian Otto, Michael Lübbert, Michael Stock
Expert Opinion on Therapeutic Targets|March 11, 2005
The silence of the genes: epigenetic disturbances in haematopoietic malignanciesBjörn Hackanson, Yalin Guo, Michael Lübbert
Current Opinion in Hematology|January 19, 2017
Innovative strategies for adverse karyotype acute myeloid leukemiaSabine Blum, Gabriele Greve, Michael Lübbert
Current Opinion in Hematology|January 12, 2010
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?Utz Krug, Michael Lübbert, Thomas Büchner
International Journal of Hematology|October 16, 2004
DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemiaBjörn Rüter, Pierre W Wijermans, Michael Lübbert
Blood|April 23, 2003
Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresesKarl-Georg Fischer, Barbara Deschler, Michael Lübbert
Haematologica|May 29, 2025
"Dexamethasing" acute myeloid leukemia: new opportunities for an "old" drugJesús Duque-Afonso, Julian List, Michael Lübbert
Pageof 25